Haemonetics Acquires Vivasure Medical for up to €185M, Expanding Percutaneous Vessel Closure Portfolio
HAE sits 78% above its 52-week low of $47.315.
Summary
Haemonetics Corporation announced the acquisition of Vivasure Medical Limited for an upfront payment of €100 million and up to €85 million in contingent consideration, enhancing its presence in the large-bore closure market.
Key Events · M&A and Partnerships · HAE
-
Acquisition of Vivasure Medical
Haemonetics Corporation acquired Vivasure Medical Limited, a company specializing in next-generation percutaneous vessel closure technology.
-
Transaction Value
The deal includes an upfront cash payment of €100 million (approximately €52 million net of prior investments) and up to an additional €85 million in contingent consideration based on performance milestones.
-
Strategic Expansion
This acquisition expands Haemonetics' complete range of closure devices, bolstering its presence in the large-bore closure market and its impact in fast-growing structural heart and endovascular procedures.
-
Financing Method
The transaction was financed through Haemonetics' available cash on hand, avoiding additional debt or equity dilution.
Analysis · HAE · Industrial Applications And Services
This acquisition is a strategic move for Haemonetics, significantly expanding its portfolio of closure devices with Vivasure's next-generation PerQseal Elite system. The technology, which has received CE Mark approval and has an FDA Premarket Approval application pending, positions Haemonetics for increased leadership in fast-growing structural heart and endovascular procedures. Financing the transaction with available cash on hand is a positive signal, indicating strong financial health and avoiding dilution. The contingent consideration structure aligns incentives for Vivasure's future performance.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HAE was trading at $84.04 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $47.32 to $87.32. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.